CFO Kyle Kline sells entire 18,542 share position in GMED at $90.00 for $1.7M; stock up 43.4% in 30 days
Kyle Kline, Senior Vice President and CFO, divested his entire remaining shareholding of 18,542 shares at $90.00, reducing his position to zero. The sale occurred amid strong recent momentum—the stock has risen 43.4% over the past 30 days and 45.6% over 90 days—yet still trades 6.0% below its 52-week high of $93.32. The company's fundamentals show robust growth with annual revenue increasing 60.6% year-over-year and generating $119.0M in net income on $769.0M in quarterly revenue. A complete liquidation by the CFO warrants investor attention given the steep valuation (P/E of 27.68) and recent appreciation, though the absence of a prior trading history in this filing limits comparative context for assessing whether this represents a shift in positioning.